CHANDAN vs NOVARTIND: Stock Comparison

CHANDAN vs NOVARTIS INDIAUpdated 18 Sept 26, 4:08 PM ISTNSE & company filings

NOVARTIS INDIA is the larger company by market capitalisation. CHANDAN shows a lower P/E, a higher ROE and a higher ROCE, while NOVARTIS INDIA shows faster revenue growth, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CHANDAN leads 5; NOVARTIND leads 7 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CHANDANNOVARTIND

Valuation lens

What price are you paying?

Market CapContext only
₹495 Cr
₹5,074 Cr
P/E RatioCHANDAN has the lower reading
22.4x
51.89x
P/B RatioCHANDAN has the lower reading
3.55x
6.2x
EPSNOVARTIND has the higher reading
₹2.74
₹13.05
Book ValueContext only
₹72.1
₹331.23
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
NOVARTIND is the larger company
₹5,074 Cr vs ₹495 Cr
P/E Ratio
CHANDAN has a lower P/E
22.4x vs 51.89x
P/B Ratio
CHANDAN has a lower P/B
3.55x vs 6.2x
EPS
NOVARTIND has higher earnings per share
₹13.05 vs ₹2.74
Revenue Growth (TTM YoY)
NOVARTIND has faster revenue growth
8% vs 0%
EPS Growth (TTM YoY)
CHANDAN has faster EPS growth
0% vs -13.8%
Qtr Sales Growth
NOVARTIND has stronger quarterly sales growth
14.64% vs -39.81%
Qtr Profit Growth
NOVARTIND has stronger quarterly profit growth
27.56% vs -10.49%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCHANDANNOVARTIND
SectorHealthcare
IndustryPharmaceuticals

Price

MetricCHANDANNOVARTIND
Live Price₹2,046.8
Day Change-1.7%
Volume76,794
52-Week High₹2,588.8
52-Week Low₹950
Distance from 52W High-20.94%

Valuation

MetricCHANDANNOVARTIND
Market Cap₹495 Cr₹5,074 Cr
P/E Ratio22.4x51.89x
P/B Ratio3.55x6.2x
EPS₹2.74₹13.05
Book Value₹72.1₹331.23
Dividend Yield0%0%

Growth

MetricCHANDANNOVARTIND
Revenue Growth (TTM YoY)0%8%
EPS Growth (TTM YoY)0%-13.8%
Qtr Sales Growth-39.81%14.64%
Qtr Profit Growth-10.49%27.56%

Profitability & Leverage

MetricCHANDANNOVARTIND
ROE16.2%11.39%
ROCE14.55%14.33%
Net Margin0%26.3%
Operating Margin15.97%36.95%
Debt to Equity0.3x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCHANDANNOVARTIND
Promoter Holding49.61% 0.06 pp0%
FII Holding0.01%0.16% 0.01 pp
DII Holding5.09% 0.06 pp1.36% 0.83 pp
Public Holding45.29% 0.13 pp27.8% 0.81 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CHANDAN and NOVARTIS INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.